GLP-1 Drugs Use, Risks, and Regulation

1. At a Glance

• GLP-1 receptor agonists (GLP-1 RAs) are a class of injectable/oral drugs that mimic the gut hormone glucagon-like peptide-1, lowering blood sugar and inducing weight loss; originally licensed for Type 2 Diabetes Mellitus (T2DM), now widely used off-label and on-label for obesity [S1][S2].
• Examinable as a Science & Tech / Health Governance issue: intersects CDSCO drug regulation, NCD burden, WHO Essential Medicines List, and pharma IPR (semaglutide patent expiry 2026 in India) [S1][S3].

2. Why in the News

• PIB Backgrounder (1 April 2026) released by Ministry of Information & Broadcasting flagging risks of unsupervised GLP-1 use in India [S1].
• Drugs Controller General of India (DCGI) intensified surveillance against unauthorised sale/online promotion of GLP-1 weight-loss drugs amid entry of generic variants [S2].
• WHO issued its first global guideline on GLP-1 medicines for obesity (1 Dec 2025) and added GLP-1s to the Essential Medicines List in Sept 2025 for T2DM in high-risk groups [S3].

3. Background & Evolution

• GLP-1 is an incretin hormone secreted by intestinal L-cells; first GLP-1 RA exenatide approved by US FDA in 2005 for T2DM.
• Liraglutide (2010), dulaglutide (2014), semaglutide (2017 injectable; 2019 oral — first oral GLP-1) expanded the class.
• Tirzepatide (2022) — a dual GIP/GLP-1 agonist — marked the next generation [S1][S2].
• Indian market entry of generics accelerated after Novo Nordisk's semaglutide patent began expiring in key markets; CDSCO approved tirzepatide (Mounjaro) for India in 2025 [S1].

4. Core Static Facts

• Drug class: GLP-1 receptor agonists / incretin mimetics [S1].
• Approved Indian molecules: Semaglutide (injection + tablet), Liraglutide, Dulaglutide, Exenatide, Tirzepatide [S2].
• Brand names: Ozempic, Wegovy, Rybelsus (semaglutide); Saxenda (liraglutide); Mounjaro/Zepbound (tirzepatide) [S2].
• Mechanism: stimulate glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, induce satiety [S1][S3].
• Approved uses: T2DM glycaemic control; chronic weight management; reduction of MACE (major adverse cardiovascular events) and CKD risk [S3].
• Indian Regulator: Central Drugs Standard Control Organisation (CDSCO) under Ministry of Health & Family Welfare; apex authority DCGI; enabling law — Drugs and Cosmetics Act, 1940 and New Drugs and Clinical Trials Rules, 2019 [S2].
• Prescriber restriction in India: only endocrinologists, internal medicine specialists, and cardiologists may prescribe [S2].
• WHO: added GLP-1s to Model List of Essential Medicines, Sept 2025; obesity affects >1 billion people globally [S3].

5. Multi-Dimensional Analysis

Scientific / Technological - Dual/triple agonists (GIP-GLP-1, glucagon-GLP-1) under trial; oral peptide delivery (Rybelsus) is a formulation breakthrough [S3]. - Emerging evidence of benefit in CKD, MASH, sleep apnoea, cardiovascular mortality [S3].

Health / Social - India has the world's second-largest diabetic population; GLP-1s offer cardio-renal protection but cost (~₹15,000–25,000/month) limits equity [S1]. - Risk of medicalisation of obesity and cosmetic misuse via influencer-driven demand [S1][S2].

Regulatory / Governance - CDSCO crackdown on online pharmacies, wellness clinics, wholesalers for off-label sale [S2]. - Schedule H/H1 prescription-only status; counterfeit and compounded versions a growing concern [S2].

Ethical - Diversion of supply from diabetics to weight-loss seekers caused global shortages of Ozempic in 2023–24 [S3]. - WHO guideline stresses multimodal chronic care, not standalone drug therapy [S3].

Economic - Generic semaglutide launch post-patent expiry expected to compress prices; boost for Indian generics industry (Sun Pharma, Cipla, Dr Reddy's pipelines) [S1].

6. Recent Developments (last 12-18 months)

• Sept 2025 — WHO adds GLP-1 RAs to Essential Medicines List for T2DM [S3].
• 1 Dec 2025 — WHO releases first global guideline on GLP-1 for obesity management [S3].
• March 2026 — DCGI advisory on regulatory surveillance over GLP-1 supply chain in India [S2].
• 1 April 2026 — PIB Backgrounder on GLP-1 use, risks, regulation [S1].

7. Prelims Hooks

• GLP-1 is secreted by intestinal L-cells, an incretin hormone [S1].
• Tirzepatide is a dual GIP/GLP-1 receptor agonist — not pure GLP-1 [S2].
• Rybelsus = first oral GLP-1 RA (semaglutide tablet) [S2].
• Apex Indian drug regulator: CDSCO, headed by DCGI, under MoHFW (not Ministry of Chemicals & Fertilizers) [S2].
• Enabling statute: Drugs and Cosmetics Act, 1940 + New Drugs & Clinical Trials Rules, 2019 [S2].
• In India, GLP-1s may be prescribed only by endocrinologists, internal medicine, cardiologists [S2].
• Known adverse effects: nausea, pancreatitis, medullary thyroid carcinoma, bowel obstruction [S2].
• WHO added GLP-1 to Essential Medicines List in September 2025 [S3].
• WHO's first global guideline on GLP-1 for obesity released 1 December 2025 [S3].
• Global obesity burden cited by WHO: >1 billion people [S3].
• GLP-1 RAs reduce risk of MACE in T2DM patients [S3].
• Semaglutide brands: Ozempic (T2DM inj), Wegovy (obesity inj), Rybelsus (oral) [S2].

8. Mains Relevance

• GS-II: Health (Issues relating to development & management of Social Sector — Health); Government policies and regulation.
• GS-III: Science & Technology — developments and applications; Pharma sector; IPR (patent expiry of biologics).
• Sample stems: 1. "GLP-1 receptor agonists have transformed diabetes and obesity care but pose regulatory dilemmas in low- and middle-income countries. Examine in the Indian context." (GS-III) 2. "Evaluate the adequacy of India's drug regulatory framework under CDSCO in addressing the boom of weight-loss pharmaceuticals." (GS-II) 3. "Discuss the ethical issues in expanding access to expensive lifestyle drugs amidst persistent under-nutrition." (GS-IV/II)

9. Related Topics to Study Next

• CDSCO & Drugs and Cosmetics Act, 1940 — parent regulatory architecture.
• WHO Model List of Essential Medicines — global health governance.
• National Programme for Prevention & Control of NCDs (NP-NCD) — diabetes burden in India.
• TRIPS & compulsory licensing — biologic patent expiry and generics.
• PLI Scheme for Pharmaceuticals & Bulk Drugs — domestic API capacity.
• Jan Aushadhi / PMBJP — affordability angle.
• Eat Right India & Fit India — obesity prevention preventive arm.
• Antimicrobial Resistance & online pharmacy regulation — analogous governance challenge.

10. Common Errors / Trap Areas

• Confusing GLP-1 (incretin) with insulin — GLP-1 is not insulin; it stimulates insulin release [S1].
• Treating tirzepatide as a GLP-1 RA only — it is a dual GIP/GLP-1 agonist [S2].
• Misattributing regulation to Ministry of Chemicals & Fertilizers (handles pharma pricing/NPPA) instead of MoHFW/CDSCO for approvals [S2].
• Assuming oral form means OTC — Rybelsus is prescription-only (Schedule H) [S2].
• Confusing Ozempic (T2DM) with Wegovy (obesity) — same molecule, different indication/dose [S2].

11. Sources

• [S1] PIB Backgrounder — GLP-1 Drugs Use, Risks, and Regulation (1 Apr 2026) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2247459 — (tier: 1)
• [S2] PIB — Regulatory Surveillance Over Weight Loss Drug (GLP-1) Supply Chain — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2244252 — (tier: 1)
• [S3] WHO — WHO issues global guideline on the use of GLP-1 medicines in treating obesity (1 Dec 2025) — https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity — (tier: 2)